0000010795-20-000019.txt : 20200507 0000010795-20-000019.hdr.sgml : 20200507 20200507132444 ACCESSION NUMBER: 0000010795-20-000019 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200507 DATE AS OF CHANGE: 20200507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BECTON DICKINSON & CO CENTRAL INDEX KEY: 0000010795 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 220760120 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-04802 FILM NUMBER: 20855571 BUSINESS ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKES STATE: NJ ZIP: 07417-1880 BUSINESS PHONE: 2018476800 MAIL ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKE STATE: NJ ZIP: 07417 10-Q 1 bdx0331202010-q.htm 10-Q Document
false--09-30Q2202000000107950.770.79140000000015000000003900000065000000331000000 0000010795 2019-10-01 2020-03-31 0000010795 exch:XNYS bdx:Notes0.174dueJune42021Member 2019-10-01 2020-03-31 0000010795 exch:XNYS us-gaap:CommonStockMember 2019-10-01 2020-03-31 0000010795 exch:XNYS bdx:Notes1.900dueDecember152026Member 2019-10-01 2020-03-31 0000010795 exch:XNYS bdx:Notes1.208dueJune42026Member 2019-10-01 2020-03-31 0000010795 exch:XNYS bdx:Notes1.401dueMay242023Member 2019-10-01 2020-03-31 0000010795 exch:XNYS bdx:Notes1.000dueDecember152022Member 2019-10-01 2020-03-31 0000010795 exch:XNYS bdx:Notes0.632dueJune42023Member 2019-10-01 2020-03-31 0000010795 exch:XNYS bdx:Notes3.020dueMay242025Member 2019-10-01 2020-03-31 0000010795 2020-03-31 0000010795 2019-09-30 0000010795 2019-01-01 2019-03-31 0000010795 2020-01-01 2020-03-31 0000010795 2018-10-01 2019-03-31 0000010795 2018-09-30 0000010795 2019-03-31 0000010795 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000010795 us-gaap:CommonStockMember 2019-03-31 0000010795 us-gaap:TreasuryStockMember 2018-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000010795 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000010795 us-gaap:TreasuryStockMember 2019-03-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-12-31 0000010795 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000010795 us-gaap:TreasuryStockMember 2018-10-01 2018-12-31 0000010795 us-gaap:RetainedEarningsMember 2018-09-30 0000010795 us-gaap:CommonStockMember 2018-12-31 0000010795 us-gaap:TreasuryStockMember 2018-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-03-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-03-31 0000010795 us-gaap:RetainedEarningsMember 2018-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-09-30 0000010795 us-gaap:CommonStockMember 2018-09-30 0000010795 us-gaap:RetainedEarningsMember 2019-03-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-10-01 2018-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-10-01 2018-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-09-30 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000010795 2018-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2018-10-01 2018-12-31 0000010795 2018-10-01 2018-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-10-01 2018-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000010795 2019-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000010795 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-09-30 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000010795 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000010795 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-12-31 0000010795 us-gaap:TreasuryStockMember 2020-03-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000010795 us-gaap:CommonStockMember 2020-03-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0000010795 us-gaap:RetainedEarningsMember 2019-09-30 0000010795 us-gaap:TreasuryStockMember 2019-10-01 2019-12-31 0000010795 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-01-01 2020-03-31 0000010795 us-gaap:RetainedEarningsMember 2020-03-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000010795 us-gaap:CommonStockMember 2019-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-09-30 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-10-01 2019-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000010795 us-gaap:CommonStockMember 2019-09-30 0000010795 us-gaap:RetainedEarningsMember 2019-12-31 0000010795 us-gaap:TreasuryStockMember 2019-09-30 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-03-31 0000010795 us-gaap:TreasuryStockMember 2019-12-31 0000010795 bdx:ShareBasedCompensationMember 2019-01-01 2019-03-31 0000010795 us-gaap:ConvertiblePreferredStockMember 2019-10-01 2020-03-31 0000010795 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-03-31 0000010795 bdx:ShareBasedCompensationMember 2018-10-01 2019-03-31 0000010795 bdx:ShareBasedCompensationMember 2020-01-01 2020-03-31 0000010795 bdx:ShareBasedCompensationMember 2019-10-01 2020-03-31 0000010795 us-gaap:ConvertiblePreferredStockMember 2018-10-01 2019-03-31 0000010795 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-03-31 0000010795 us-gaap:ConvertiblePreferredStockMember 2020-03-31 0000010795 us-gaap:SubsequentEventMember 2020-05-01 0000010795 bdx:WomensHealthProductClaimsMember 2020-03-31 0000010795 us-gaap:OtherOperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000010795 us-gaap:OtherOperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000010795 bdx:CompensatoryMember bdx:WomensHealthProductClaimsMember 2018-04-01 2018-04-30 0000010795 bdx:FilterProductClaimsMember 2020-03-31 0000010795 bdx:FilterProductClaimsMember 2019-10-01 2020-03-31 0000010795 bdx:WomensHealthProductClaimsMember 2018-04-01 2018-04-30 0000010795 bdx:PunitiveMember bdx:WomensHealthProductClaimsMember 2018-04-01 2018-04-30 0000010795 bdx:HerniaProductClaimsMember 2020-03-31 0000010795 bdx:ProductsandorServicesMember 2020-04-01 2020-03-31 0000010795 2020-04-01 2020-03-31 0000010795 bdx:ConsumablesMember 2020-04-01 2020-03-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-03-31 0000010795 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 us-gaap:CorporateNonSegmentMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember 2018-10-01 2019-03-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember 2019-10-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2019-10-01 2020-03-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 us-gaap:CorporateNonSegmentMember 2019-10-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 country:US 2019-10-01 2020-03-31 0000010795 us-gaap:NonUsMember 2018-10-01 2019-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 country:US 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2018-10-01 2019-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 us-gaap:NonUsMember 2019-10-01 2020-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2019-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 bdx:IVFluidsMember country:US 2019-01-01 2019-03-31 0000010795 bdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember country:US 2019-01-01 2019-03-31 0000010795 bdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember country:US 2018-10-01 2019-03-31 0000010795 bdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000010795 bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember us-gaap:NonUsMember 2018-10-01 2019-03-31 0000010795 bdx:AdvancedBioprocessingMember 2019-01-01 2019-03-31 0000010795 bdx:IVFluidsMember country:US 2018-10-01 2019-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 country:US 2020-01-01 2020-03-31 0000010795 us-gaap:NonUsMember 2020-01-01 2020-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 country:US 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 us-gaap:NonUsMember 2019-01-01 2019-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2020-01-01 2020-03-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2020-01-01 2020-03-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-01-01 2019-03-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-01-01 2019-03-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-01-01 2019-03-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2020-01-01 2020-03-31 0000010795 bdx:LifeSciencesMember 2019-10-01 2020-03-31 0000010795 us-gaap:OtherOperatingIncomeExpenseMember 2018-10-01 2019-03-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2018-10-01 2019-03-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2019-10-01 2020-03-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2019-10-01 2020-03-31 0000010795 bdx:OtherInitiativesMember 2019-10-01 2020-03-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:CRBardIncMember 2019-09-30 0000010795 us-gaap:EmployeeSeveranceMember bdx:CRBardIncMember 2020-03-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:CRBardIncMember 2019-10-01 2020-03-31 0000010795 us-gaap:OtherRestructuringMember bdx:CRBardIncMember 2019-10-01 2020-03-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2020-03-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2019-10-01 2020-03-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2020-03-31 0000010795 us-gaap:OtherRestructuringMember bdx:CRBardIncMember 2019-09-30 0000010795 bdx:CRBardIncMember 2020-03-31 0000010795 us-gaap:OtherRestructuringMember bdx:CRBardIncMember 2020-03-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2019-09-30 0000010795 bdx:OtherInitiativesMember 2020-03-31 0000010795 bdx:OtherInitiativesMember 2019-09-30 0000010795 bdx:CRBardIncMember 2019-10-01 2020-03-31 0000010795 bdx:CRBardIncMember 2019-09-30 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2019-09-30 0000010795 bdx:LifeSciencesMember 2020-03-31 0000010795 bdx:MedicalMember 2019-09-30 0000010795 bdx:MedicalMember 2019-10-01 2020-03-31 0000010795 bdx:LifeSciencesMember 2019-09-30 0000010795 bdx:MedicalMember 2020-03-31 0000010795 bdx:InterventionalMember 2020-03-31 0000010795 bdx:InterventionalMember 2019-10-01 2020-03-31 0000010795 bdx:InterventionalMember 2019-09-30 0000010795 bdx:ProductRightsMember 2020-03-31 0000010795 us-gaap:TrademarksMember 2020-03-31 0000010795 us-gaap:DevelopedTechnologyRightsMember 2020-03-31 0000010795 us-gaap:TrademarksMember 2020-03-31 0000010795 us-gaap:DevelopedTechnologyRightsMember 2019-09-30 0000010795 us-gaap:CustomerRelationshipsMember 2019-09-30 0000010795 bdx:ProductRightsMember 2019-09-30 0000010795 us-gaap:CustomerRelationshipsMember 2020-03-31 0000010795 us-gaap:IntellectualPropertyMember 2019-09-30 0000010795 us-gaap:TrademarksMember 2019-09-30 0000010795 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2020-03-31 0000010795 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2019-09-30 0000010795 us-gaap:IntellectualPropertyMember 2020-03-31 0000010795 us-gaap:TrademarksMember 2019-09-30 0000010795 bdx:FixedToFloatingMember us-gaap:FairValueHedgingMember 2020-03-31 0000010795 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember 2020-03-31 0000010795 us-gaap:ForeignExchangeContractMember 2019-09-30 0000010795 us-gaap:ForeignExchangeContractMember 2020-03-31 0000010795 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember 2020-03-31 0000010795 us-gaap:CurrencySwapMember 2019-09-30 0000010795 us-gaap:CurrencySwapMember 2020-03-31 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-10-01 2020-03-31 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-31 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000010795 us-gaap:CurrencySwapMember 2020-01-01 2020-03-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2020-01-01 2020-03-31 0000010795 us-gaap:CurrencySwapMember 2019-01-01 2019-03-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2019-01-01 2019-03-31 0000010795 us-gaap:CurrencySwapMember 2019-10-01 2020-03-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2019-10-01 2020-03-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2018-10-01 2019-03-31 0000010795 us-gaap:CurrencySwapMember 2018-10-01 2019-03-31 0000010795 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember 2019-09-30 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-09-30 0000010795 srt:MinimumMember 2019-10-01 2020-03-31 0000010795 srt:MaximumMember 2019-10-01 2020-03-31 0000010795 us-gaap:RevolvingCreditFacilityMember 2020-03-31 0000010795 bdx:TermLoanFacilityMember 2020-01-01 2020-03-31 0000010795 bdx:TermLoanFacilityMember 2020-03-31 0000010795 bdx:TermLoanFacilityMember 2020-03-20 0000010795 us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2020-04-01 0000010795 srt:MaximumMember 2020-03-31 0000010795 srt:MinimumMember 2020-03-31 bdx:segment iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number 001-4802
Becton, Dickinson and Company
(Exact name of registrant as specified in its charter)
New Jersey
 
22-0760120
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
 
 
 
 
1 Becton Drive,
Franklin Lakes,
New Jersey
07417-1880
 
(201)
847-6800
(Address of principal executive offices) (Zip Code)
 
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
 
Trading Symbol
 
Name of Each Exchange on Which Registered
Common stock, par value $1.00
 
BDX
 
New York Stock Exchange
1.000% Notes due December 15, 2022
 
BDX22A
 
New York Stock Exchange
1.900% Notes due December 15, 2026
 
BDX26
 
New York Stock Exchange
1.401% Notes due May 24, 2023
 
BDX23A
 
New York Stock Exchange
3.020% Notes due May 24, 2025
 
BDX25
 
New York Stock Exchange
0.174% Notes due June 4, 2021
 
BDX/21
 
New York Stock Exchange
0.632% Notes due June 4, 2023
 
BDX/23A
 
New York Stock Exchange
1.208% Notes due June 4, 2026
 
BDX/26A
 
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No   ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
  
Accelerated filer
 
Non-accelerated filer
 
 
Smaller reporting company
 
Emerging growth company
 
 
 
 
 
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  ☒
There were 271,776,378 shares of Common Stock, $1.00 par value, outstanding at March 31, 2020.

 



BECTON, DICKINSON AND COMPANY
FORM 10-Q
For the quarterly period ended March 31, 2020
TABLE OF CONTENTS
 
 
Page
Number
Part I.
FINANCIAL INFORMATION
 
 
 
 
Item 1.
 
 
 
 
 
 
Item 2.
Item 3.
Item 4.
 
 
 
Part II.
 
 
 
 
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
 
 
 
 

2



ITEM 1. FINANCIAL STATEMENTS
BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
Millions of dollars
 
March 31,
2020
 
September 30,
2019
Assets
(Unaudited)
 
 
Current Assets:
 
 
 
Cash and equivalents
$
2,351

 
$
536

Restricted cash
88

 
54

Short-term investments
6

 
30

Trade receivables, net
2,160

 
2,345

Inventories:
 
 
 
Materials
601

 
544

Work in process
357

 
318

Finished products
1,836

 
1,717

 
2,793

 
2,579

Prepaid expenses and other
1,156

 
1,119

Total Current Assets
8,555

 
6,664

Property, Plant and Equipment
11,262

 
11,128

Less allowances for depreciation and amortization
5,598

 
5,469

Property, Plant and Equipment, Net
5,664

 
5,659

Goodwill
23,415

 
23,376

Developed Technology, Net
10,545

 
11,054

Customer Relationships, Net
3,261

 
3,424

Other Intangibles, Net
567

 
500

Other Assets
1,509

 
1,088

Total Assets
$
53,516

 
$
51,765

Liabilities and Shareholders’ Equity
 
 
 
Current Liabilities:
 
 
 
Short-term debt
$
4,357

 
$
1,309

Payables, accrued expenses and other current liabilities
4,398

 
4,345

Total Current Liabilities
8,755

 
5,655

Long-Term Debt
16,809

 
18,081

Long-Term Employee Benefit Obligations
1,253

 
1,272

Deferred Income Taxes and Other Liabilities
5,747

 
5,676

Commitments and Contingencies (See Note 5)


 


Shareholders’ Equity
 
 
 
Preferred stock
2

 
2

Common stock
347

 
347

Capital in excess of par value
16,288

 
16,270

Retained earnings
12,868

 
12,913

Deferred compensation
23

 
23

Common stock in treasury - at cost
(6,158
)
 
(6,190
)
Accumulated other comprehensive loss
(2,419
)
 
(2,283
)
Total Shareholders’ Equity
20,951

 
21,081

Total Liabilities and Shareholders’ Equity
$
53,516

 
$
51,765

Amounts may not add due to rounding.
See notes to condensed consolidated financial statements

3



BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
Millions of dollars, except per share data
(Unaudited)
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2020
 
2019
 
2020
 
2019
Revenues
$
4,253

 
$
4,195

 
$
8,479

 
$
8,355

Cost of products sold
2,520

 
2,221

 
4,766

 
4,408

Selling and administrative expense
1,025

 
1,089

 
2,146

 
2,161

Research and development expense
264

 
252

 
535

 
510

Acquisitions and other restructurings
75

 
101

 
161

 
191

Other operating expense, net

 
396

 

 
61

Total Operating Costs and Expenses
3,884

 
4,059

 
7,607

 
7,332

Operating Income
370

 
136

 
871

 
1,024

Interest expense
(134
)
 
(171
)
 
(270
)
 
(342
)
Interest income
2

 
18

 
3

 
6

Other (expense) income, net
(38
)
 
20

 
(11
)
 
30

Income Before Income Taxes
200

 
3

 
594

 
718

Income tax provision (benefit)
17

 
(17
)
 
134

 
98

Net Income
183

 
20

 
461

 
619

Preferred stock dividends
(38
)
 
(38
)
 
(76
)
 
(76
)
Net income (loss) applicable to common shareholders
$
145

 
$
(18
)
 
$
385

 
$
544

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic Earnings (Loss) per Share
$
0.53

 
$
(0.07
)
 
$
1.42

 
$
2.02

Diluted Earnings (Loss) per Share
$
0.53

 
$
(0.07
)
 
$
1.40

 
$
1.98

Dividends per Common Share
$
0.79

 
$
0.77

 
$
1.58

 
$
1.54

Amounts may not add due to rounding.
See notes to condensed consolidated financial statements

4



BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Millions of dollars
(Unaudited)
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2020
 
2019
 
2020
 
2019
Net Income
$
183

 
$
20

 
$
461

 
$
619

Other Comprehensive (Loss) Income, Net of Tax
 
 
 
 
 
 
 
Foreign currency translation adjustments
(125
)
 
76

 
(99
)
 
42

Defined benefit pension and postretirement plans
17

 
13

 
33

 
28

Cash flow hedges
(109
)
 
(1
)
 
(70
)
 

Other Comprehensive (Loss) Income, Net of Tax
(218
)
 
88

 
(136
)
 
70

Comprehensive (Loss) Income
$
(35
)
 
$
108

 
$
325

 
$
689

Amounts may not add due to rounding.
See notes to condensed consolidated financial statements

5



BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Millions of dollars
(Unaudited)
 
Six Months Ended
March 31,
 
2020
 
2019
Operating Activities
 
 
 
Net income
$
461

 
$
619

Adjustments to net income to derive net cash provided by operating activities:
 
 
 
Depreciation and amortization
1,067

 
1,126

Share-based compensation
141

 
152

Deferred income taxes
(136
)
 
(109
)
Change in operating assets and liabilities
(258
)
 
(531
)
Pension obligation
49

 
(202
)
Gain on sale of business

 
(335
)
Product liability-related charge

 
331

Other, net
(128
)
 
(25
)
Net Cash Provided by Operating Activities
1,196

 
1,027

Investing Activities
 
 
 
Capital expenditures
(395
)
 
(362
)
Proceeds from divestitures, net

 
477

Other, net
(147
)
 
(85
)
Net Cash (Used for) Provided by Investing Activities
(542
)
 
30

Financing Activities
 
 
 
Change in credit facility borrowings
210

 

Proceeds from long-term debt and term loans
1,900

 

Payments of debt and term loans
(305
)
 
(905
)
Dividends paid
(505
)
 
(491
)
Other, net
(90
)
 
(135
)
Net Cash Provided by (Used for) Financing Activities
1,210

 
(1,532
)
Effect of exchange rate changes on cash and equivalents and restricted cash
(15
)
 
5

Net increase (decrease) in cash and equivalents and restricted cash
1,849

 
(469
)
Opening Cash and Equivalents and Restricted Cash
590

 
1,236

Closing Cash and Equivalents and Restricted Cash
$
2,439

 
$
767

Amounts may not add due to rounding.
See notes to condensed consolidated financial statements

6



BECTON, DICKINSON AND COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2020
Note 1 – Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2019 Annual Report on Form 10-K. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
Note 2Accounting Changes
New Accounting Principle Adopted
In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019 and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 15.
New Accounting Principles Not Yet Adopted
In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.
In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The standard is effective for the Company on October 1, 2020, but early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption.

7



Note 3Shareholders' Equity
Changes in certain components of shareholders' equity for the first two quarters of fiscal years 2020 and 2019 were as follows:
 
Common
Stock  Issued
at Par Value
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Deferred
Compensation
 
Treasury Stock
(Millions of dollars)
Shares (in
thousands)
 
Amount
Balance at September 30, 2019
$
347

 
$
16,270

 
$
12,913

 
$
23

 
(76,260
)
 
$
(6,190
)
Net income

 

 
278

 

 

 

Common dividends ($0.79 per share)

 

 
(215
)
 

 

 

Preferred dividends

 

 
(38
)
 

 

 

Common stock issued for share-based compensation and other plans, net

 
(32
)
 

 
1

 
758

 
(38
)
Share-based compensation

 
82

 

 

 

 

Common stock held in trusts, net (a)

 

 

 

 
(12
)
 

Balance at December 31, 2019
$
347

 
$
16,320

 
$
12,938

 
$
24

 
(75,514
)
 
$
(6,228
)
Net income

 

 
183

 

 

 

Common dividends ($0.79 per share)

 

 
(215
)
 

 

 

Preferred dividends

 

 
(38
)
 

 

 

Common stock issued for share-based compensation and other plans, net

 
(91
)
 

 
(1
)
 
573

 
70

Share-based compensation

 
58

 

 

 

 

Common stock held in trusts, net (a)

 

 

 

 
30

 

Balance at March 31, 2020
$
347

 
$
16,288

 
$
12,868

 
$
23

 
(74,911
)
 
$
(6,158
)
 
Common
Stock  Issued
at Par Value
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Deferred
Compensation
 
Treasury Stock
(Millions of dollars)
Shares (in
thousands)
 
Amount
Balance at September 30, 2018
$
347

 
$
16,179

 
$
12,596

 
$
22

 
(78,463
)
 
$
(6,243
)
Net income

 

 
599

 

 

 

Common dividends ($0.77 per share)

 

 
(207
)
 

 

 

Preferred dividends

 

 
(38
)
 

 

 

Common stock issued for share-based compensation and other plans, net

 
(97
)
 

 
2

 
851

 
9

Share-based compensation

 
92

 

 

 

 

Common stock held in trusts, net (a)

 

 

 

 
(12
)
 

Effect of change in accounting principles

 

 
68

 

 

 

Balance at December 31, 2018
$
347

 
$
16,174

 
$
13,018

 
$
24

 
(77,624
)
 
$
(6,235
)
Net income

 

 
20

 

 

 

Common dividends ($0.77 per share)

 

 
(208
)
 

 

 

Preferred dividends

 

 
(38
)
 

 

 

Common stock issued for share-based compensation and other plans, net

 
(57
)
 
(1
)
 
(1
)
 
618

 
42

Share-based compensation

 
60

 

 

 

 

Common stock held in trusts, net (a)

 

 

 

 
50

 

Balance at March 31, 2019
$
347

 
$
16,177

 
$
12,792

 
$
23

 
(76,955
)
 
$
(6,192
)
(a)
Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.

8



The components and changes of Accumulated other comprehensive income (loss) for the first two quarters of fiscal years 2020 and 2019 were as follows:
(Millions of dollars)
Total
 
Foreign Currency
Translation
 
Benefit Plans
 

Cash Flow Hedges
Balance at September 30, 2019
$
(2,283
)
 
$
(1,256
)
 
$
(1,005
)
 
$
(23
)
Other comprehensive income before reclassifications, net of taxes
63

 
26

 

 
37

Amounts reclassified into income, net of taxes
19

 

 
17

 
2

Balance at December 31, 2019
$
(2,202
)
 
$
(1,230
)
 
$
(988
)
 
$
16

Other comprehensive loss before reclassifications, net of taxes
(237
)
 
(125
)
 

 
(111
)
Amounts reclassified into income, net of taxes
19

 

 
17

 
2

Balance at March 31, 2020
$
(2,419
)
 
$
(1,355
)
 
$
(971
)
 
$
(93
)
(Millions of dollars)
Total
 
Foreign Currency
Translation
 
Benefit Plans
 

Cash Flow Hedges
Balance at September 30, 2018
$
(1,909
)
 
$
(1,162
)
 
$
(729
)
 
$
(17
)
Other comprehensive (loss) income before reclassifications, net of taxes
(32
)
 
(35
)
 
3

 
(1
)
Amounts reclassified into income, net of taxes
14

 

 
13

 
1

Balance at December 31, 2018
$
(1,927
)
 
$
(1,197
)
 
$
(714
)
 
$
(16
)
Other comprehensive income (loss) before reclassifications, net of taxes
74

 
76

 

 
(2
)
Amounts reclassified into income, net of taxes
14

 

 
13

 
1

Balance at March 31, 2019
$
(1,839
)
 
$
(1,121
)
 
$
(701
)
 
$
(17
)
The amounts of foreign currency translation recognized in other comprehensive income during the three and six months ended March 31, 2020 and 2019 included net gains (losses) relating to net investment hedges. The amounts recognized in other comprehensive income relating to cash flow hedges during the three and six months ended March 31, 2020 related to forward starting interest rate swaps. Additional disclosures regarding the Company's derivatives are provided in Note 12.
 
 
 
 
 
 
 
 

Note 4 – Earnings per Share
The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2020
 
2019
 
2020
 
2019
Average common shares outstanding
272,014

 
269,882

 
271,555

 
269,454

Dilutive share equivalents from share-based plans
3,023

 

 
3,618

 
4,975

Average common and common equivalent shares outstanding – assuming dilution
275,037

 
269,882

 
275,173

 
274,429

 
 
 
 
 
 
 
 
Share equivalents excluded from the diluted shares outstanding calculation because the result would have been antidilutive:
 
 
 
 
 
 
 
Mandatory convertible preferred stock
11,685

 
11,685

 
11,685

 
11,685

Share-based plans

 
4,405

 

 


In accordance with the terms of the Company's mandatory convertible preferred stock, on the mandatory conversion date of May 1, 2020, the 2.475 million mandatory convertible preferred shares that were issued in May 2017 in connection with the Company's acquisition of C.R. Bard, Inc. ("Bard") were converted into 11.703 million shares of BD common stock.

9




Note 5Contingencies
Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.
In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.
Product Liability Matters
The Company believes that certain settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available.
Hernia Product Claims
As of March 31, 2020, the Company is defending approximately 16,815 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2020 in various state and/or federal courts, with the first trial currently scheduled for June 2020 in Rhode Island. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity.
Women’s Health Product Claims
As of March 31, 2020, the Company is defending approximately 580 product liability claims involving the Company’s line of pelvic mesh devices. The majority of those claims are currently pending in various federal court jurisdictions, and a coordinated proceeding in New Jersey State Court, but claims are also pending in other state court jurisdictions. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately 1,005 filed and unfiled claims that have been asserted or threatened against the Company but lack sufficient information to determine whether a pelvic mesh device of the Company is actually at issue.
The claims identified above also include products manufactured by both the Company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the Company. Medtronic has an obligation to defend and indemnify the Company with respect to any product defect liability relating to products its subsidiaries had manufactured. In July 2015, the Company reached an agreement with Medtronic in which Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the

10



Company under supply agreements with Medtronic. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. As of March 31, 2020, the Company has paid Medtronic $141 million towards these potential settlements. The Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products.
As of March 31, 2020, the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 15,220 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements.
Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated throughout 2020 in state and federal courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ($33 million compensatory; $35 million punitive). The Company is in the process of appealing that verdict. The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months, which may potentially include consolidated trials.
During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company.
Filter Product Claims
As of March 31, 2020, the Company is defending approximately 1,785 product liability claims involving the Company’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims were previously pending in an MDL in the United States District Court for the District of Arizona, but those MDL claims either have been, or are in the process of being, remanded to various federal jurisdictions. Filter Product Claims are also pending in various state court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. On May 31, 2019, the MDL Court ceased accepting direct filings or transfers into the Filter Product Claims MDL and, as noted above, remands for non-settled cases have begun and are expected to continue over the next three months. Federal and state court trials are scheduled throughout 2020. As of March 31, 2020, the Company entered into settlement agreements and/or settlement agreements in principle for approximately 7,300 cases. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months.
In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their

11



medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.
In connection with the settlement of a prior litigation with certain of the Company's insurance carriers, an agreement with the Company's insurance carriers was reached to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage.
Other Legal Matters
Since early 2013, the Company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be.
In July 2017, a civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec® and QuantaFloTM devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity.
The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations.
On February 27, 2020, a putative class action captioned Kabak v. Becton, Dickinson and Company, et al., Civ. No. 2:20-cv-02155 (SRC) (CLW), was filed in the U.S. District Court for the District of New Jersey against the Company and certain of its officers. The complaint, which purports to be brought on behalf of all persons (other than defendants) who purchased or otherwise acquired the Company's common stock from November 5, 2019 through February 5, 2020, asserts claims for purported violations of Sections 10 and 20 of the Securities Exchange Act of 1934 and SEC Rule 10b-5 promulgated thereunder, and seeks, among other things, damages and costs. The complaint alleges that defendants concealed material information regarding AlarisTM infusion pumps, including that (1) certain pumps exhibited software errors, (2) the Company was investing in remediation efforts as opposed to other enhancements and (3) the Company was thus reasonably likely to recall certain pumps and/or experience regulatory delays. These alleged omissions, the complaint asserts, rendered certain public statements about the Company’s business, operations and prospects false or misleading, causing investors to purchase stock at an inflated price. The Company believes these claims are without merit and intends to vigorously defend this action.
On April 27, 2020, three putative stockholders, including the named plaintiff in the Kabak complaint, filed motions to be appointed lead plaintiff and for their counsel to be appointed lead counsel pursuant to the Private Securities Litigation Reform Act of 1995. Those motions remain pending.
The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters.
Litigation Reserves
The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.
In the second and fourth quarters of fiscal year 2019, the Company recorded pre-tax charges to Other operating expense, net, of approximately $331 million and $582 million, respectively, related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The Company recorded these charges based on additional information obtained during the second and fourth quarters of fiscal year 2019.

12



Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $2.3 billion at March 31, 2020 and $2.5 billion at September 30, 2019. These accruals, which are generally long-term in nature, are largely recorded within Deferred Income Taxes and Other Liabilities on the Company's condensed consolidated balance sheets. As of March 31, 2020 and September 30, 2019, the Company had $87 million and $53 million, respectively, in qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash. The Company's expected recoveries related to product liability claims and related legal defense costs were approximately $117 million and $150 million at March 31, 2020 and September 30, 2019, respectively. A substantial amount of these expected recoveries at March 31, 2020 and September 30, 2019 related to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. The expected recoveries at March 31, 2020 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements.
Note 6Revenues
The Company’s policies for recognizing sales have not changed from those described in the Company’s 2019 Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Measurement of Revenues
The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectable. Such amounts are not material to the Company's consolidated financial results.
The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The impact of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.
Effects of Revenue Arrangements on Consolidated Balance Sheets
Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets.
Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time are immaterial to the Company's consolidated financial results. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets.
Remaining Performance Obligations
The Company's obligations relative to service contracts and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately $1.7 billion at March 31, 2020. The Company expects to recognize the majority of this revenue over the next three years.
Within the Company's Medication Management Solutions, Medication Delivery Solutions, Integrated Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.7 billion at March 31, 2020.  This revenue will be recognized over the customer relationship period.
Disaggregation of Revenues
A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.

13



Note 7Segment Data
The Company's organizational structure is based upon three principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.
Effective October 1, 2019, Life Sciences joined its former Preanalytical Systems and Diagnostic Systems organizational units to create a new Integrated Diagnostic Solutions organizational unit which focuses on driving growth and innovation around integrated specimen management to diagnostic solutions. The Integrated Diagnostic Solutions organizational unit consists of the following principal product lines:
Organizational Unit
 
Principal Product Lines
Integrated Diagnostic Solutions
 
Integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays for testing of respiratory infections; microbiology laboratory automation and plated media for clinical and industrial applications.
Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.
 
Three Months Ended March 31,
(Millions of dollars)
2020
 
2019
 
United States
 
International
 
Total
 
United States
 
International
 
Total
Medical
 
 
 
 
 
 
 
 
 
 
 
Medication Delivery Solutions (a)
$
518

 
$
386

 
$
904

 
$
482

 
$
446

 
$
928

Medication Management Solutions (a)
449

 
119

 
568

 
499

 
118

 
617

Diabetes Care
142

 
137

 
278

 
137

 
133

 
270

Pharmaceutical Systems
91

 
309

 
400

 
93

 
273

 
366

Total segment revenues
$
1,200

 
$
951

 
$
2,151

 
$
1,211

 
$
969

 
$
2,180

 
 
 
 
 
 
 
 
 
 
 
 
Life Sciences
 
 
 
 
 
 
 
 
 
 
 
Integrated Diagnostic Solutions
 
 
 
 
 
 
 
 
 
 
 
Preanalytical Systems
$
208

 
$
192

 
$
400

 
$
171

 
$
195

 
$
366

Diagnostic Systems
206

 
228

 
434

 
180

 
209

 
389

Total Integrated Diagnostic Solutions
413

 
420

 
833

 
350

 
404

 
755

Biosciences
108

 
172

 
280

 
120

 
177

 
297

Total segment revenues
$
522

 
$
591

 
$
1,113

 
$
470

 
$
582

 
$
1,052

 
 
 
 
 
 
 
 
 
 
 
 
Interventional
 
 
 
 
 
 
 
 
 
 
 
Surgery (b)
$
249

 
$
63

 
$
312

 
$
242

 
$
66

 
$
308

Peripheral Intervention (b)
242

 
157

 
399

 
225

 
162

 
387

Urology and Critical Care (b)
202

 
76